Abstract
Determine the prevalence of anti-CCP isotype IgA and its relation to peripheral arthritis in patients with inflammatory bowel disease (IBD). In a population-based cohort of 654 patients with a definitive diagnosis of IBD, 521 patients were clinically examined by a rheumatologist 6 years after IBD diagnosis Blood serum samples of 416 of these patients were available and analyzed. Antibodies against cyclic citrullinated peptides anti-CCP IgA were determined in the serum samples by an immunofluoresence technique ELiA TM. Among the 416 IBD patients, 5 had a positive IgA class anti-CCP, giving a prevalence of 1.2%. Only four anti-CCP IgA-negative patients had a positive rheumatoid factor IgM, compared to two out of five anti-CCP IgA-positive IBD patients (10.2% versus 40.0%; p = 0.002). There were four patients with rheumatoid arthritis, two in each patient population (0.5% versus 40.0%; p = 0.0007). Four of the five anti-CCP IgA-positive IBD patients had arthritis, two with rheumatoid arthritis, and two with other arthritis. In this first study on the prevalence of IgA anti-CCP antibodies in IBD patients, we demonstrate a low prevalence, but these antibodies are associated with arthritis and positive IgM rheumatoid factor in IBD patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Palm Ø, Moum B, Jahnsen J, Gran JT (2001) The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatol (Oxford) 40(11):1256–1261
Zendman AJ, van Venrooij WJ, Pruijn GJ (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatol (Oxford) 45(5):20–25
van Venrooij WJ, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6(1):37–41
Lakos G, Soós L, Fekete A, Szabó Z, Zeher M, Horváth IF, Dankó K, Kapitány A, Gyetvai A, Szegedi G, Szekanecz Z (2008) Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clin Exp Rheumatol 26(2):253–260
Koutroubakis IE, Karmiris K, Bourikas L, Kouroumalis EA, Drygiannakis I, Drygiannakis D (2007) Antibodies against cyclic citrullinated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations. Inflamm Bowel Dis 13(4):504–505
Papamichael K, Tsirogianni A, Papasteriades C, Mantzaris GJ (2009) Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis. Eur J Gastroenterol Hepatol 22:705–709
Gabriel SE. Classification of Rheumatic Diseases. In: Klippel JH, Dieppe P. Rheumatology. second ed, Vol. 1. London: Mosby 1998; 3.1–4.
Kastbom A, Reckner-OlssonSvärd AA, Skogh T (2008) Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 10(4):R75, Epub 2008 Jul 4
Acknowledgments
We thank Bjarne Kristensen in Phadia ApS for cooperation, technical support and supplying the kit for analysis of anti-CCP IgA. We thank the laboratory staff at Kong Christian 9th. Gigthospital in Graasten, Denmark for support. We also thank Kvinnherrad and Stord Rheumatism Association for their financial support. We thank IBSEN Study Group for their cooperation and making it able for us to perform this study.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haga, HJ., Palm, Ø. & Peen, E. Prevalence of IgA class antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease (IBD). Clin Rheumatol 30, 955–957 (2011). https://doi.org/10.1007/s10067-011-1696-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1696-3